320 W 10th Avenue
Columbus, OH 43210
Phone: (614) 293-7807
Associate Professor-Clinical, Hematology
Malignant Hematology: Lymphoma
I joined the faculty of the Division of Hematology in 2009 as an Assistant Professor of Clinical Medicine. I am currently seeking promotion on the clinician scholar pathway of the clinical track, to Associate Professor based on the accomplishments which I will describe herein.
I completed my MD degree in 2002 and my Internal Medicine residency in 2005 at The Ohio State University. From 2005-2006, I joined the Division of Hospital Medicine as an Assistant Professor of Clinical Medicine. I then returned to training and completed my Hematology and Oncology Fellowship from 2006-2009, serving as the Chief Fellow during my final year. During fellowship, I focused on clinical research under the mentorship of Dr. Kristie Blum and a translational research project in the laboratory of Dr. Robert Baiocchi. I joined the Division of Hematology as a faculty member in 2009. My current clinical focus is in Hodgkin and non-Hodgkin lymphoma. My research interests are novel therapeutics and outcomes research in lymphoma.
Teaching and Mentorship:
From the standpoint of medical student education, I have been the Associate Block director for Host Defense in the LeadServeInspire (LSI) curriculum since 2013, a position associated with 0.025 FTE. From 2012 to 2014, I served as a preceptor for the Medicine Mentors program where I mentored small groups of 8-10 medical students during their 3rd Internal Medicine rotations on a weekly basis. Teaching included direct observation of patient interactions and small group didactic teaching and case presentations. I received 0.10 FTE for my efforts in this program. From 2012 – 2014, I was the module editor and provided oversight to the Medical Student Scientist Program (MSTP) Hematology curriculum which included development and editing of an independent study module and writing the examination. Currently, I have an expert Educator position in the College of Medicine with the goal of transitioning the MSTP program into the LSI curriculum (0.10 FTE). I served as a Longitudinal Practice preceptor for a medical student from 2013-2015. I am currently a Longitudinal Group preceptor from 2014-2016, a position with 0.075 FTE where my responsibilities include an every other week teaching session with a small group of 12-14 medical students starting in their first year focused on didactic teaching, developing interviewing and physical examination skills, as well as clinical reasoning. I am a trained faculty rater for the OSCE and regularly rate sessions. In terms of clinical teaching, I have attended on the Hematology 1 inpatient service which includes students, residents and fellows in 2 week blocks approximately 4 times per year since 2009 with direct bedside and clinical teaching. I received a Faculty teaching award in 2010. I have given numerous lectures to medical students, residents, and fellows. In order to further develop and improve upon my teaching skills, I was a selected participant in the Stanford Clinical Teaching Faculty Workshop in June 2014. Additionally, I attended the American Society of Hematology Item Writing Workshop in June 2014 which was designed to teach techniques for writing board–style examination questions. I have mentored four fellows in continuity clinic, I am mentoring a resident on a retrospective research project with a manuscript currently in preparation, and I mentored two medical students on education based projects. I am an elected faculty member of the Lead Serve and Inspire (LSI) Part I Academic Program Committee, 2014 – 2016, and I have been a member of the Housestaff Education Committee since 2011.
The focus of my research is novel therapeutics and outcomes in the field of B-cell non-Hodgkin’s lymphoma and Hodgkin’s lymphoma with a focus on indolent lymphomas. Currently, I am the principle investigator on several clinical trials including a multisite CTEP sponsored phase I study of ibrutinib in combination with lenalidomide in patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma. I serve as the principle investigator for an investigator initiated phase I/II trial combining milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody for the treatment of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma which was recently published in the British Journal of Haematology. I am also the institutional principle investigator for two active clinical trials including, 1) a phase I dose escalation study of immunotherapy with IMMU-114 in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, and 2) A randomized, double-blind, placebo-controlled phase 3 study of the Bruton’s tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. I will be the principle investigator on two clinical trials currently in development including a phase Ib study of ACP-196 alone or in combination with rituximab in subjects with follicular lymphoma and a phase I/2 study evaluating brentuximab vedotin in combination with the PD-1 inhibitor nivolumab in patients with relapsed or refractory Hodgkin lymphoma after failure of frontline therapy. Additionally, I have been the institutional principle investigator on Alliance cooperative group clinical trials, including a recent phase II trial of ofatumumab in previously untreated follicular non-Hodgkin’s and I am a co-investigator on numerous clinical trials. In terms of outcomes based research, I am currently a co-investigator on an R01 funded multidisciplinary project entitled, “Computer-based assessment of tumor microenvironment (TME) in follicular lymphoma”. I also serve as the principle investigator for The Ohio State University – James Cancer Hospital Lymphoma Database, a large prospective database which will facilitate outcomes research in the area of lymphoma. I have several nontherapeutic retrospective projects underway including examining outcomes for non-Hodgkin lymphoma patients treated with bendamustine and evaluating immunohistochemical and epigenetic markers to determine prognosis in classical Hodgkin lymphoma utilizing archival tissue specimens. My current efforts are focused in the development of novel clinical trials for patients with Hodgkin’s and non-Hodgkin’s lymphoma.
I have served on numerous committees at the University and Division level. Currently, I am the Hematology representative to the Data Safety Review Committee which is responsible for ensuring the safe conduct of investigator initiated studies at The Ohio State University. I am currently a member of the Hematology Division Operational Excellence Committee as the representative for the lymphoma group. I previously served as a member of the Antibiotic Committee from 2009 – 2010, the Herbal Medication Workgoup from 2009 – 2010, the Evidence Based Practice Medicine Committee from 2011- 2012, the Hematology Admissions Quality Committee in 2014, and the NPSF Provider Stakeholder Committee in 2014.
On the national level, I served as an ad hoc reviewer to multiple high impact journals including the New England Journal of Medicine, the British Journal of Haematology, Leukemia and Lymphoma, and Blood. I have participated as a consultant in Advisory Boards for Celgene, Inc. and Seattle Genetics to provide advice on novel therapeutics and clinical trial development in lymphoma. I have been invited to serve on the Independent Data Monitoring Committee for an international clinical trial, a Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy by GlaxoSmithKline / Novartis, based on my national reputation in the field of lymphoma and my experience with Data Safety Monitoring and clinical trial oversight. On the regional level, I have been an invited speaker for the Ohio State American Society of Hematology Annual Review. I was also an invited speaker at patient education sessions for the Leukemia and Lymphoma Society and the Lymphoma Research Foundation.
In summary, based on my accomplishments in research, education and mentoring, and service, I am seeking promotion to Associate Professor on the clinical track in the clinician scholar pathway. I have been very active in medical student education in didactic lectures, small group teaching, and curricular development, as well as mentoring and teaching residents and fellows. My clinical research in lymphoma currently includes numerous clinical trials including 4 investigator initiated trials that I designed and developed, 4 pharmaceutical sponsored studies, 2 co-operative group sponsored studies, and three retrospective studies. I have a productive service record for the division and medical center.
|2009 - present||, The Ohio State University.|
|2009 - present||, The Ohio State University.|
|2009 - present||, The Ohio State University.|
|2009 - present||, The Ohio State University.|
|2013 - present||, Ohio State University College of Medicine.|
|2014 - present||David Bond, The Ohio State University.|
|2010 - 2011||Deborah Stephens, The Ohio State University.|
|2011 - 2012||Kerry Rogers, The Ohio State University.|
|2012 - 2013||Kate Panzer, The Ohio State University.|
|2014||Kevin Koehler, The Ohio State University.|
|2014 - 2015||Wil Santivasi, The Ohio State University.|
|2014 - 2015||Zubin Yavar, The Ohio State University.|
|present||Advanced Cardiac Life Support Certificate: American Heart Association|
|present||Basic Cardiac Life Support Certificate: American Heart Association|
|2005 - present||Board Certification: American Board of Internal Medicine|
|2009 - present||Board Certification: American Board of Internal Medicine|
|2010 - present||Board Certification: American Board of Internal Medicine|
|2002 - 2005||MD Training Certificate: # 57.005787 (Inactive): State Medical Board of Ohio|
|2005 - 2017||Doctor of Medicine: License # 35.085172: State Medical Board of Ohio|
|08/01/2009||Outpatient Hematology Clinic (James Cancer Hospital)|
|09/01/2009||Hematology Inpatient Service (James Cancer Hospital)|
Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-κB
Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma
A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma.
Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).
Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity
A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
Complete Response (CR) to Induction Therapy in Patients (pts) with Myc plus and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).
Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL).
Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.
A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)
A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis
A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma
A phase 1/1b study of combined rituximab, bendamustine, and ibrutinib in patients with previously untreated and relapsed/refractory non-Hodgkin's lymphoma
Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies
Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)
|1998||B.S., Tulane University|
|2002||M.D., The Ohio State University|
|2009 - present||Clinical Lymphoma and Myeloma|
|2012 - present||Current Medical Literature – Leukemia & Lymphoma|
|2012 - present||Cancer Control: Journal of the Moffitt Cancer Center|
|2012 - present||New England Journal of Medicine|
|2012 - present||Hematology Board Review Manual|
|2014 - present||Leukemia and Lymphoma|
|2014 - present||Blood|
|2015 - present||British Journal of Haematology|
|2007 - present||Robyn D. Howson Housestaff Humanism Award. The Ohio State University.|
|2008 - present||Amgen Hematology & Oncology Fellowship Stipend Support Program. Amgen Pharmaceuticals.|
|2008 - present||American Society of Hematology Clinical Research Training Institute. American Society of Hematology.|
|2008 - 2009||Chief Fellow. The Ohio State University.|
|2010 - present||Outstanding Achievement in Patient Service. The Ohio State University.|
|2010 - present||Faculty Award for Teaching Excellence. The Ohio State University.|
|2013 - present||Outstanding Achievement in Patient Service. The Ohio State University.|
|January 2009||Alinari L, Christian B, Yu B, Shin J, Hertlein EK, Lapalombella R, Yan F, Lesinski G, Zhang X, Lozanski G, Muthusamy N, Goldenberg DM, Byrd JC, and Baiocchi RA."Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-κB" .|
|January 2010||Racke FR, Simpson S, Christian B, Blum KA, and Zhao W."Evidence Suggesting Long Latency Periods Prior to Development of Mantle Cell Lymphoma" .|
Low Grade Lymphomas
Rituximab: Past, Present, and Future
Ask the Doctor / Lymphoma Research Foundation
Clinical Updates in Lymphoma
|present||Consulting / Advisory Board. Seattle Genetics, Inc..|
|present||Consulting / Advisory Board. Celgene, Inc..|
|2015 - present||Independent Data Monitoring Committee. GlaxoSmithKline / Novartis.|